Ani Pharmaceuticals (ANIP) Net Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed Net Margin across 16 years of filings, most recently posting 9.28% for Q2 2026.

• In Q2 2026, Net Margin rose 543.0% year-over-year to 9.28%; the TTM figure through Jun 2026 stood at 11.03% (up 1262.0% YoY), while the FY2025 annual figure was 8.74%, up 1202.0% from the prior year.
• Net Margin came in at 9.28% for Q2 2026 at Ani Pharmaceuticals, down from 12.42% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 12.95% in Q1 2024 to a low of 31.85% in Q1 2022.
• Average Net Margin over 5 years is 0.54%, with a median of 2.41% recorded in 2025.
• The largest YoY upside for Net Margin was 3499 bps in 2022 against a maximum downside of 3200 bps in 2022.
• Over 5 years, Net Margin stood at 4.93% in 2022, then soared by 112 bps to 0.57% in 2023, then plunged by 1085 bps to 5.61% in 2024, then surged by 299 bps to 11.13% in 2025, then dropped by 17 bps to 9.28% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 9.28% in Q2 2026, 12.42% in Q1 2026, and 11.13% in Q4 2025.